Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Neurocrine Biosciences
Biotech
Neurocrine, Idorsia part ways 2 years after double phase 2 fails
Two years after Idorsia and Neurocrine’s calcium channel blocker flunked a pair of phase 2 studies, the biotechs have finally decided to part ways.
James Waldron
Oct 29, 2024 7:15am
Neurocrine's bid to save schizophrenia prospect fails
Sep 13, 2024 7:30am
Neurocrine's KarXT rival hits in phase 2—but only at low dose
Aug 28, 2024 7:53am
Roche, Vir, Neurocrine & more—Chutes & Ladders
May 31, 2024 8:30am
Neurocrine-Takeda antidepressant hits main mark in phase 2 trial
Apr 23, 2024 10:44am
Double whammy for Neurocrine as Takeda, Xenon pacts fail
Nov 10, 2023 7:22am
